October 2nd 2022, 2:29pm
Research now is addressing how subsequent therapies can meet needs of patients with Hodgkin lymphoma who progress after early lines of treatment.
October 1st 2022, 4:06pm
In comparison with conventional transplant options, Orca-T may be more effective with a lower probability of infection in patients with hematologic malignancies.
October 1st 2022, 2:22pm
Chimeric antigen receptor T-cell therapy is one such newer class of therapy to be introduced into the treatment paradigm for multiple myeloma, and bispecific antibodies are the expected next class of treatments to emerge in the clinic.
September 30th 2022, 7:43pm
When choosing a treatment regimen for follicular lymphoma, an individualized approach is necessary, according to Loretta J. Nastoupil, MD.
September 30th 2022, 7:00pm
As the brentuximab vedotin plus AVD combination gains widespread use, clinicians should recognize the toxicities, such as the risk of neutropenic fever or peripheral neuropathy, according to Alison Moskowitz, MD.
September 30th 2022, 5:30pm
Novel targets continue to emerge through clinical trials in peripheral T0cell lymphoma, in particular EZH 1 and EZH 2 inhibitors, which have strong single-agent efficacy.
September 30th 2022, 5:00pm
AUGMENT-101 demonstrates the potential of menin inhibitors for the treatment of patients with acute myeloid leukemia.
September 30th 2022, 4:00pm
Chimeric antigen receptor T-cell therapy provides a new option for patients with relapsed/refractory B-cell lymphoma.